Global News Hubb
Advertisement Banner
  • Home
  • Politics
  • Finance
  • Technology
  • Contact
No Result
View All Result
  • Home
  • Politics
  • Finance
  • Technology
  • Contact
No Result
View All Result
Wellnessnewshubb
No Result
View All Result
Home Politics

Biosplice sees a pair of osteoarthritis trials fail

admin by admin
November 20, 2022
in Politics



Biosplice’s bid to transform the treatment of everything from arthritis to cancer ran into a snag this week, with the San Diego biotech announcing that its experimental osteoarthritis drug failed to benefit patients in a pair of Phase 3 clinical trials.

The results, presented at the American College of Rheumatology conference in Philadelphia, show that the small-molecule drug lorecivivint failed to significantly soothe the pain of osteoarthritis patients. Both trials were randomized, placebo-controlled studies conducted across multiple medical research centers — the gold standard of scientific evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED





Source link

Previous Post

IFC launches $225m platform to strengthen Africa’s VC ecosystem

Next Post

It’s now or never, America | Opinions

Next Post

It’s now or never, America | Opinions

Recommended

Health care workers deserve protection from violence

3 months ago

Peruvian prosecutors want Castillo’s wife held in pre-trial detention — MercoPress

3 weeks ago

© 2022 Global News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • Politics
  • Finance
  • Technology
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • Politics
  • Finance
  • Technology
  • Contact

© 2022 Global News Hubb All rights reserved.